Market research
QURE Uniqure NV
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 70.2232
- Dividend yield
- Not available
- Beta
- 0.94
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL0010696654
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 70.2232
- Dividend yield
- Not available
- Beta
- 0.94
About
About Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the QURE discussion.
5 years, 4 months ago
uniQure N.V is currently in a long term downtrend where the price is trading 24.2% below its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.4.
uniQure N.V's total revenue rose by 1198.5% to $34M since the same quarter in the previous year.
Its net income has increased by 98.3% to $-699K since the same quarter in the previous year.
Finally, its free cash flow fell by 42.5% to $-40M since the same quarter in the previous year.
Based on the above factors, uniQure N.V gets an overall score of 3/5.